Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Up Today?
By the Top Tier Newswire AI Desk · July 22, 2026 at 9:55 AM ET · reviewed against 7 wire stories
ARROWHEAD PHARMACEUT (ARWR) is up +21.78% in the latest session. Our newswire has captured 7 stories on ARWR across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 70/100).
Arrowhead Pharmaceuticals (ARWR) surged 21.78% to $90.75 in early trading on Monday, driven by positive topline results from two Phase 3 trials of its lipid-lowering therapy plozasiran. The drug demonstrated a median triglyceride reduction of up to 81% and a complete elimination of acute pancreatitis events in high-risk patients. The results support the company’s plan to seek broader FDA approval and a supplemental new drug application in the U.S. before year-end.
What Happened
Arrowhead Pharmaceuticals reported strong outcomes from its SHASTA-3 and SHASTA-4 Phase 3 studies evaluating plozasiran in patients with severe hypertriglyceridemia. Patients receiving 25 mg doses every three months experienced durable and consistent reductions in triglyceride levels. The company emphasized that these results could lead to expanded labeling and broader use of the therapy. The news was widely covered in the financial press and generated enthusiasm among retail traders, who viewed the findings as a major breakthrough. The stock opened at $74.73 and quickly climbed to a session high of $93.53 before settling near $90.77 in late morning trading.
What The Data Shows
The stock’s intraday performance showed a sharp and sustained upward move, with volume of 1.4 million shares, or 0.7 times the 3-month average. The 52-week range is $14.30 to $87.83, meaning the current price is near the upper end of its historical range. The company remains unprofitable, with a trailing 12-month net margin of -48.4% and an EPS of -2.17. Revenue has grown 14.1% in the trailing 12 months. The stock’s beta of 1.27 suggests it is more volatile than the broader market. No unusual options activity or insider buying was reported in the last 90 days, though one insider sold $228,000 worth of shares in May.
What To Watch
Arrowhead plans to release detailed data from the Phase 3 trials on August 30. The company also announced a webcast for its fiscal 2026 third-quarter results, which ended June 30. Investors will be watching for regulatory updates and the strength of coverage from analysts, including recent Buy ratings from Stifel and JPMorgan.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
ARWR · Jul 22 session (5-min) · +19.40% vs prior close · updated 8:44 PM ETAI sentiment, last 36h · averaged over 7 stories · 70/100 bullish
The headlines behind the move
Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
7d agoStocktwits NewsBULLISH 73Product/PR
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval
The biotech firm reported positive topline results from two Phase 3 studies evaluating its hypertriglyceridemia therapy.
7d agoInvestorsHubBULLISH 73Earnings
Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR)
Arrowhead Pharmaceuticals shares surged after Phase 3 studies showed plozasiran significantly reduced triglyceride levels and acute pancreatitis events, supporting plans for a U.S. label expansion.
7d agoSeeking AlphaBULLISH 73Product/PR
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug
Arrowhead Pharmaceuticals (ARWR) stock jumps as the company posts a late-stage trial win for lipid drug plozasiran, hurting shares of Ionis (IONS). Read more here.
7d agoInvesting.com MarketsBULLISH 73Product/PR
Arrowhead Pharmaceuticals stock jumps on Phase 3 trial results
Arrowhead Pharmaceuticals stock jumps on Phase 3 trial results
7d agoMarketChameleonBULLISH 78Product/PR
Plozasiran Achieves Up to 81% Triglyceride Reduction in Arrowhead’s Phase 3 Studies—100% Drop in Acute Pancreatitis for Highest-Risk Patients
July 22, 2026
Arrowhead Pharmaceuticals’ Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in severe hypertriglyceridemia showed a median triglyceride reduction as high as 81% and a complete elimination of acute pancreatitis events in the highest-risk group, with no new safety concerns. Full results will be presented at ESC 2026.
7d agoStockTitanBULLISH 67Product/PR
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia | ARWR Stock News
Patients received 25 mg every three months; Arrowhead plans a U.S. FDA supplemental new drug application before year-end, with detailed data set for Aug. 30.
8d agoStockTitanNEUTRAL 50General
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results | ARWR Stock News
The fiscal 2026 third quarter ended June 30; access the live audio webcast on Arrowhead’s investor page, with a replay about two hours later.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →